Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and aim</h3><p>The efficacy of prenatal antiviral therapy (AVT) for preventing the vertical transmission of hepatitis B virus (HBV) is well demonstrated. However, data are limited regarding the safety of postpartum cessation of AVT, which may induce alanine aminotransferase (ALT) elevation. We aimed to investigate the necessity of prolonging maternal AVT after delivery.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Chronic hepatitis B mothers at the immune‐tolerant phase with HBV DNA levels > 6 log<sub>10</sub> IU/ml were prospectively enrolled and received AVT during the third trimester until delivery. Patients were offered to discontinue AVT either at delivery or postpartum week (PPW) 6. In addition, mothers who deferred AVT during pregnancy served as the control group. All mothers were followed until postpartum week 52 for clinical and virological parameters of hepatitis flares. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Among 118 mothers recruited, 91 received AVT with 53 (group A) and 24 (group B) discontinue their treatment at delivery and postpartum week 6, respectively. Twenty‐seven mothers who deferred AVT during pregnancy were followed as the control (group C). Of 104/118 mothers who completed the study, 50% (52/104) had postpartum elevated ALT levels, which were mild and moderate except 6/104 (5.77%) of patients had levels <span>></span> 5 times the upper limit of normal. 70% (36/52) of the ALT flares occurred within 12 weeks after delivery. In subgroup analyses, the freuquency of ALT elevation were similar among the groups A vs. B vs. C [50.9% (27/53) vs. 58.3% (14/24) vs 40.7% (11/27), respectively; <i>P</i> = 0.447], as well as the mean peak ALT level (108.4 / 74.1 / 126.7 U/L in groups A/B/C, respectively; <i>P</i> = 0.291). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Although postpartum ALT flares were common for mothers with or without AVT during pregnancy, most cases of ALT elevation were mild to moderate. Our study observed that extending AVT to postpartum week 6 did not affect maternal outcomes and ATV should be discontinued at birth. Close monitoring is warrant as severe flares rarely occurred.</p><p><a class="linkBehavior" href="http://ClinicalTrials.gov">ClinicalTrials.gov</a> number: NCT03468907. </p><p>This article is protected by copyright. All rights reserved.</p></section>

Baseline Hepatitis B Virus Titer Predicts Initial Postpartum Hepatic Flare: A Multicenter Prospective Study.

Effect of Prophylactic Antiviral Intervention on T Cell Immunity in Hepatitis B Virus-Infected Pregnant Women

[A real-world study on the features of postpartum hepatitis flares in pregnant women with chronic HBV infection]

Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases

Serum Alanine Aminotransferase and Hepatitis B DNA Flares in Pregnant and Postpartum Women with Chronic Hepatitis B

Hepatic Flare after Telbivudine Withdrawal and Efficacy of Postpartum Antiviral Therapy for Pregnancies with Chronic Hepatitis B Virus

Incidence and predictors of elevated postpartum alanine aminotransferase in chronic hepatitis B mothers: a prospective study protocol

Pregnancy Outcome of Women with Chronic Hepatitis B Who Discontinued Antiviral Treatment Before or in the Early Pregnancy

Comparison of HBV-DNA and HBeAg As Antiviral Therapeutic Indicators among HBV-infected Pregnant Women: a Systematic Review and Meta-Analysis

Postpartum hepatitis flares in mothers with chronic hepatitis B infection

Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection

[A Survey of the Current Status of Research on the Diagnosis and Treatment of Hepatitis C Virus Antibody-Positive Pregnant Women].

Kinetic Changes of Viremia and Viral Antigens of Hepatitis B Virus During and after Pregnancy.

Virological Determinants of Spontaneous Postpartum E Antigen Seroconversion and Surface Antigen Seroclearance in Pregnant Women Infected with Hepatitis B Virus.

Association of gestational hepatitis B virus infection and antiviral therapy with pregnancy outcomes: A retrospective study

The relation of the frequency and functional molecules expression on plasmacytoid dendritic cells to postpartum hepatitis in women with HBeAg-positive chronic hepatitis B virus infection

Comparison of HBV-specific T cell reactivity across the pregnant, postpartum and non-pregnant women with chronic HBV infection

The safety of antiviral therapy and drug withdrawal for the prevention of mother‐to‐child transmission of HBV during pregnancy

Maternal Hepatitis B E Antigen Can Be an Indicator for Antiviral Prophylaxis of Perinatal Transmission of Hepatitis B Virus

Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment

Different Interventional Criteria for Chronic Hepatitis B Pregnant Women with HBeAg(+) or HBeAg(-)